This company listing is no longer active
Diurnal Group Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
1.4%
Tasa de crecimiento de los beneficios
28.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.5% |
| Tasa de crecimiento de los ingresos | 51.1% |
| Rentabilidad financiera | -77.0% |
| Margen neto | -353.8% |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Diurnal Group (LON:DNL) Will Have To Spend Its Cash Wisely
Aug 13
Shareholders May Not Be So Generous With Diurnal Group plc's (LON:DNL) CEO Compensation And Here's Why
Nov 13Companies Like Diurnal Group (LON:DNL) Can Afford To Invest In Growth
Feb 25What Can We Learn About Diurnal Group's (LON:DNL) CEO Compensation?
Feb 04Diurnal Group plc (LON:DNL): When Will It Breakeven?
Jan 14Diurnal Group (LON:DNL) Shareholders Have Enjoyed A 88% Share Price Gain
Dec 25Estimating The Fair Value Of Diurnal Group plc (LON:DNL)
Dec 02Desglose de ingresos y gastos
Cómo gana y gasta dinero Diurnal Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 5 | -17 | 10 | 12 |
| 31 Mar 22 | 5 | -15 | 10 | 11 |
| 31 Dec 21 | 5 | -13 | 9 | 10 |
| 30 Sep 21 | 5 | -12 | 9 | 9 |
| 30 Jun 21 | 4 | -10 | 8 | 7 |
| 31 Mar 21 | 5 | -7 | 8 | 6 |
| 31 Dec 20 | 6 | -5 | 8 | 5 |
| 30 Sep 20 | 6 | -4 | 8 | 5 |
| 30 Jun 20 | 6 | -4 | 7 | 5 |
| 31 Mar 20 | 4 | -6 | 7 | 5 |
| 31 Dec 19 | 2 | -8 | 6 | 5 |
| 30 Sep 19 | 2 | -10 | 6 | 7 |
| 30 Jun 19 | 1 | -12 | 7 | 9 |
| 31 Mar 19 | 1 | -14 | 7 | 10 |
| 31 Dec 18 | 0 | -16 | 7 | 12 |
| 30 Sep 18 | 0 | -15 | 7 | 11 |
| 30 Jun 18 | 0 | -15 | 7 | 10 |
| 31 Mar 18 | 0 | -13 | 6 | 10 |
| 31 Dec 17 | 0 | -10 | 5 | 9 |
| 30 Sep 17 | 0 | -10 | 4 | 9 |
| 30 Jun 17 | 0 | -9 | 4 | 8 |
| 31 Mar 17 | 0 | -9 | 3 | 7 |
| 31 Dec 16 | 0 | -9 | 2 | 6 |
| 30 Sep 16 | 0 | -8 | 2 | 5 |
| 30 Jun 16 | 0 | -7 | 2 | 4 |
Ingresos de calidad: DNL is currently unprofitable.
Margen de beneficios creciente: DNL is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DNL is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.
Acelerando crecimiento: Unable to compare DNL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: DNL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.5%).
Rentabilidad financiera
Alta ROE: DNL has a negative Return on Equity (-76.98%), as it is currently unprofitable.